FDA Approves Wider Humira Use Despite Efficacy Concerns
The U.S. Food and Drug Administration on Friday announced it had approved Abbott Laboratories Inc.'s blockbuster anti-inflammatory drug Humira to treat the bowel disease ulcerative colitis, despite agency researchers' previous concerns...To view the full article, register now.
Already a subscriber? Click here to view full article